MissionIR Articles
-
D-Wave Quantum Inc. (NYSE: QBTS) Reports Increase in Fiscal Year 2024 Bookings and First-Ever Customer Purchase of an Advantage(TM) Quantum Computer
D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, reported a 120%+ increase in bookings for fiscal year 2024 compared to 2023 figures.…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and…
-
MissionIRNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Secures New Public Safety Contracts in Kentucky
SuperCom (NASDAQ: SPCB), a global provider of e-Government, IoT, and cybersecurity solutions, announced two new contracts with key Kentucky agencies to deploy its advanced public safety technologies. The contracts, which displaced incumbent competitors, demonstrate SuperCom’s growing…
-
MissionIRNewsBreaks – Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Ownership Led by Individual Investors Holding Majority Stake
Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) was featured in a recent article by Simply Wall St. The publication describes Platinum’s ownership structure, explaining that the company is primarily owned by individual investors,…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product
Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the…
-
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced participation at the H.C. Wainwright 26th Annual Global Investment Conference. The conference,…
-
MissionIRNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth
InMed Pharmaceuticals’ (NASDAQ: INM) subsidiary BayMedica is positioned amid a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth. The company…
-
SuperCom Ltd. (NASDAQ: SPCB) Reports Q2, H1 Earnings Growth, Record Profit
Electronic monitoring (“EM”) technology innovator SuperCom (NASDAQ: SPCB) is celebrating impressive developments in 2024, reporting “substantial improvements” in its gross profit, operating income, and net income as it secures new orders and contracts from government and judicial…
-
MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Quantum AI Product Roadmap Enhancements Highlighted in Syndicated Broadcast
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, is featured in a NetworkNewsAudio (“NNA”) broadcast. NNA broadcasts are designed…
-
Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s…
-
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food and Drug…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Securities Purchase Agreements Worth Estimated $1.98M
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused…
-
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call
Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug-platform company developing novel therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting the results of its recent phase 2/3 Alzheimer’s study. The study…
-
Did Institutional Investors Drop The Ball With McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)?
Mid-cap mining company, McEwen Mining (NYSE: MUX) (TSX: MUX) recently reported its first quarter results for 2024. (https://ibn.fm/ZDZ5U). It wasn’t a stellar quarter for the company’s gold/silver/copper operations. However, in pricing in this news it…
-
MissionIRNewsBreaks – Zoned Properties Inc. (ZDPY) Bridging Gaps in Cannabis Space with Requisite Real Estate and Consultation Services
Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, acquires value-add real estate within the regulated U.S. cannabis industry with selective development innovation and aspirations to spearhead direct-to-consumer real…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured on the Virtual Investor Lunch Break: The…
-
MissionIRNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Announces Agreements to Add Charging Terminal Access for Users of Growing Da Ge App
FingerMotion (NASDAQ: FNGR), a mobile services and data company, through its contractually controlled entity, Shanghai JiuGe Information Technology Co. Ltd., is facilitating the expanded use of the Da Ge app. According to the announcement, the…
-
MissionIRNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Announces Fourth-Quarter 2023 Preliminary Results Continue Revenue Growth Trend
Freight Technologies (NASDAQ: FRGT) is reporting its preliminary financial results for the fourth quarter of 202, the period ending Dec. 31, 2023. According to the report, Fr8Tech is showing its third consecutive quarter of notable…
-
Bravo Multinational Inc. (BRVO) to Launch New Streaming Service to Generate Long-Term Shareholder Value
Video streaming revenue worldwide has exploded over the last decade, with an estimated value of $108.50 billion in 2024. By 2027, the market is expected to reach $137.70 billion, growing at a CAGR of 8.27%…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces January Analyst, Investor Webinar
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of both inflammation and immunology. During the webinar, SCNI CEO Amir Reichman will present an overview of the company’s performance throughout the year 2023, along with…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS) to Debut Mudra Experience Studio at MWC Barcelona 2026
- MissionIRNewsBreaks – Beeline Holdings Inc. (NASDAQ: BLNE) Featured by Streetwise Reports for Rapid Revenue Growth and Fintech Expansion
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer
- MissionIRNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Completes $1M AI Edge System Delivery to U.S. Government in 15 Days
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer